Neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab shows improved pathologic responses and MRD signal utility in cisplatin-ineligible MIBC: Primary SunRISe-4 analysis
SunRISe-4 reports higher pCR, pOR, and 1‑year RFS for neoadjuvant TAR‑200 plus cetrelimab versus cetrelimab alone in cisplatin‑ineligible/refusing MIBC, with urinary and circulating tumor DNA MRD correlating with outcomes.